If You Invested $1,000 in Summit Therapeutics Inc (SMMT)
This article provides details on the historical performance of investing $1,000 in Summit Therapeutics Inc. (SMMT) over various periods, showing returns and compound annual growth rates. It also gives an overview of Summit Therapeutics, highlighting its focus on oncology, its lead investigational drug ivonescimab, ongoing clinical trials, and its collaborations with Akeso Inc. and GSK plc. The company operates in the biotechnology sector and aims to address unmet medical needs in cancer treatment.
Understanding Momentum Shifts in (SMMT)
Quantitative Research Desk has analyzed Summit Therapeutics Inc. (NASDAQ: SMMT), indicating stable neutral readings in shorter horizons may signal an easing of a long-term weak bias. The analysis highlights an exceptional risk-reward setup targeting a 30.3% gain versus 0.3% risk, with specific strategies for position trading, momentum breakout, and risk hedging provided. Support level is being tested, and if it holds, resistance is expected next.
Has Summit Therapeutics (SMMT) Become Undervalued As It Pulls Its $500 Million Offering?
Summit Therapeutics (SMMT) recently canceled a US$500 million public offering, causing its shares to fall by over 14% in 30 days, despite significant three-year gains. The cancellation raises questions about the stock's valuation, as some estimates suggest it is 51.2% undervalued with a fair value of $29.18, based on the potential of its lead drug ivonescimab. However, concerns about its single-drug focus and unresolved FDA decisions could challenge this undervalued narrative, prompting investors to assess risks and rewards.
Summit Therapeutics finance chief tops list of public CFO pay in 2025
Manmeet Soni, CFO of oncology firm Summit Therapeutics, was the highest-paid finance chief among publicly traded American firms in 2025, with total compensation near $250 million. This compensation was largely driven by performance-based stock awards. The report by C-Suite Comp also highlighted a trend of increasing CFO pay, especially in the tech sector and mid-market companies, with performance incentives being a major component.
Bernstein raises Summit Therapeutics stock price target on trial outlook
Bernstein SocGen Group has increased its price target for Summit Therapeutics (NASDAQ:SMMT) to $9.80 from $7.70, while maintaining an "Underperform" rating, based on an increased probability of success for its HARMONi-3 trial. The firm’s analysis assumes that results from Akeso’s China-only HARMONi-6 trial can be extrapolated to Summit's global trial, despite concerns about the PD-1+VEGF class's limited benefit in older patients and competitive market landscape. This update comes amidst other recent news including a $500 million stock offering and varied analyst perspectives on the company.
Summit Therapeutics (SMMT): A $500 Million Stock Offering Pulled Just One Day After Filing
Summit Therapeutics Inc. (SMMT) withdrew a $500 million proposed public offering one day after its announcement, citing unfavorable market conditions. The offering was intended to fund research and development for ivonescimab, a bispecific antibody for cancer treatment that recently showed positive Phase 3 data in China. However, concerns were raised regarding the applicability of China-only trial data to a global patient population.
5 Most Promising Healthcare Stocks According to Wall Street Analysts
This article identifies Summit Therapeutics Inc. (NASDAQ: SMMT) as one of the most promising healthcare stocks according to Wall Street analysts. Summit's lead drug, ivonescimab, which targets cancer cells, recently showed positive Phase 3 data from a China-based lung cancer trial with a 34% reduction in the risk of death. However, concerns exist about the applicability of China-only trial data to global patient populations, especially after the company withdrew a proposed $500 million public offering due to unfavorable market conditions.
SMMT Financials: Revenue Breakdown, Margins & Competitor Comparison
This article provides a financial overview of Summit Therapeutics Inc (SMMT), detailing its revenue breakdown, profitability margins, and a comparison with competitors like BMRN and ARWR. The company currently has no data on its revenue streams, and its gross, operating, and net margins are not available, though its Return on Equity is -270.95%. Summit Therapeutics Inc has a market capitalization of $10.67B.
Avoiding Lag: Real-Time Signals in (SMMT) Movement
Stock Traders Daily's Quantitative Research Desk provides an analysis of Summit Therapeutics Inc. (SMMT), highlighting near-term strong sentiment challenging persistent mid and long-term weakness. The article details an exceptional 87.0:1 risk-reward short setup and offers three distinct AI-generated trading strategies: Position Trading, Momentum Breakout, and Risk Hedging. It also includes multi-timeframe signal analysis with support and resistance levels.
Summit Therapeutics Inc (SMMT) Earnings Forecast: Future EPS & Revenue Growth Estimates
Summit Therapeutics Inc (SMMT) has an earnings forecast score of 7.22, placing it in the 308th position out of 389 companies in the Biotechnology & Medical Research industry. Analysts have set an average price target of $34.50 for SMMT, with ratings predominantly suggesting a "Buy" trend. The company's previous quarter's EPS was significantly below market expectations, and the upcoming quarter's EPS is also projected to be negative.
Should Summit Therapeutics’ Canceled US$500 Million Equity Offering Reshape SMMT Investors’ View on Financing Strategy?
Summit Therapeutics recently withdrew a US$500 million equity offering after announcing positive Phase II/III data for its lead cancer drug, ivonescimab. This decision highlights the company's balancing act between funding needs and market conditions, especially with no current revenue and high cash burn. The withdrawn offering means Summit will rely more on its existing US$713.4 million cash balance as it approaches the November 14, 2026 PDUFA decision for ivonescimab.
Summit Therapeutics stockholders approve directors and incentive plan
Summit Therapeutics stockholders held their 2026 Annual Meeting where they elected nine directors, ratified PricewaterhouseCoopers LLP as their accounting firm, and approved executive compensation. Shareholders also backed an amendment to the 2020 Stock Incentive Plan to increase shares by 8 million for equity-based compensation. Despite these positive corporate events, an AI analyst notes the stock (SMMT) faces challenges due to weak financial performance and bearish technicals, classifying it as "Neutral" with a current price target of $30.00.
Summit Therapeutics (SMMT) Raises $500 Million Through Public Offering
Summit Therapeutics Inc. (SMMT) initiated an underwritten public offering of common stock valued at $500 million, with J.P. Morgan, Goldman Sachs & Co., and Citigroup managing the process. This offering comes after Cantor Fitzgerald reaffirmed its Overweight rating following positive Phase 3 HARMONi-6 trial data for ivonescimab in non-small cell lung cancer. The company is actively developing ivonescimab, a bispecific antibody, and is awaiting results from its global Phase 3 HARMONi-3 trial in late 2026.
Insider Buying: Summit Therapeutics Co-CEO, President & Director Bought US$1.5m Of Shares
Summit Therapeutics' Co-CEO, President & Director, Mahkam Zanganeh, recently purchased US$1.5 million worth of shares at an average price of US$14.60. This transaction, although a small percentage increase in her holding, signals confidence, especially when combined with a prior US$262 million insider purchase by the Co-CEO & Executive Chairman at a higher price. The company also boasts significant insider ownership at 79%, suggesting strong alignment between management and shareholder interests despite the company currently making losses.
Summit Therapeutics (SMMT) Raises $500 Million Through Public Offering
Summit Therapeutics Inc. (NASDAQ: SMMT) recently completed an underwritten public offering, raising $500 million. The biopharma company, which is focused on developing oncology therapies, is offering 100% of the shares directly. This financial move follows a reaffirmed "Overweight" rating from Cantor Fitzgerald after promising Phase 3 HARMONi-6 trial data for its ivonescimab treatment in non-small cell lung cancer.
Summit Therapeutics stock rises after CEO share purchase
Summit Therapeutics Inc. (NASDAQ:SMMT) shares rose 4% after co-chief executive officer Robert Duggan purchased 3.81 million shares of common stock at $13.12 per share on June 12. Following this transaction, Duggan directly owns 573.88 million shares of the company and is classified as a 10% owner. The filing also detailed his indirect holdings through various family trusts.
Summit Therapeutics (SMMT) Co-CEO Robert Duggan buys 3.81M shares in open market
Summit Therapeutics Co-CEO Robert W. Duggan purchased 3,810,000 shares of the company's common stock at $13.12 per share in an open-market transaction, totaling approximately $49.99 million. This transaction significantly increases his direct holdings to over 573 million shares. The filing also details indirect holdings through various trusts and family members, though Duggan disclaims beneficial ownership of these indirect holdings except for any pecuniary interest.
Summit Therapeutics co-CEO Robert Duggan buys $49.9m in stock
Robert Duggan, co-CEO of Summit Therapeutics, recently acquired 3.81 million shares for $49.9 million, bringing his direct holdings to over 573 million shares. This purchase occurred while the stock was near its 52-week low. The company also announced a $500 million public offering amidst mixed analyst ratings concerning its trial data.
Summit Therapeutics (NASDAQ: SMMT) investors approve directors and 8M-share incentive plan boost
Summit Therapeutics (NASDAQ: SMMT) shareholders approved all proposals at their 2026 Annual Meeting. Key decisions included the election of nine directors, ratification of PricewaterhouseCoopers LLP as the independent auditor, and a non-binding advisory approval of executive compensation. Crucially, investors also sanctioned an amendment to the 2020 Stock Incentive Plan, increasing the number of shares available for future equity awards by 8,000,000.
SMMT Jumps As Ivonescimab Trial Success Fuels Financing Drive
Summit Therapeutics Inc. (SMMT) shares rose by 7.72% following promising clinical trial results for its drug ivonescimab, which showed significant efficacy in treating NSCLC and colorectal cancer. The company plans a $500 million stock offering to fund development, and while dilution is a risk, the strong clinical data present major upside catalysts. Despite being a development-stage biotech with no revenue, analyst sentiment is positive due to ivonescimab's potential.
Summit Therapeutics co-CEO Zanganeh acquires $49.98m in shares
Summit Therapeutics co-CEO Mahkam Zanganeh recently acquired 3.81 million shares for approximately $49.98 million, increasing her indirect holdings. This transaction follows a significant $500 million public offering by the company, which has resulted in mixed analyst reactions and a decline in share price. Zanganeh's indirect stake now totals over 573 million shares, with additional holdings through trusts and direct ownership.
Summit Therapeutics(SMMT.US) 10% Shareholder Buys US$49.99 Million in Common Stock
A 10% shareholder of Summit Therapeutics (SMMT.US) recently purchased $49.99 million worth of common stock. This significant insider buying activity may indicate confidence in the company's future prospects from a major investor.
Co-CEO Mahkam Zanganeh (SMMT) reports spouse’s 3.81M-share open-market buy
Mahkam Zanganeh, Co-CEO of Summit Therapeutics (SMMT), reported her spouse's indirect open-market purchase of 3.81 million shares at $13.12 each, totaling approximately $49.99 million. This significant transaction was detailed in a Form 4 filing, which also clarified Zanganeh disclaims beneficial ownership beyond her pecuniary interest for these indirect holdings. The purchase reflects a substantial increase in exposure to SMMT, bolstering family and trust-held stakes alongside Zanganeh's direct shares.
Summit gains after nearly $50M insider buy (SMMT:NASDAQ)
Summit Therapeutics (SMMT) shares rebounded after co-CEO Robert Duggan disclosed purchasing nearly $50 million worth of company shares. This significant insider buy on Friday helped the cancer drug developer recover recent losses. The purchase was revealed in a regulatory filing.
Summit Therapeutics Co-Chief Executive Officer Purchased Shares Worth Over $49M
Robert W. Duggan, Co-Chief Executive Officer and a 10% owner of Summit Therapeutics (SMMT), purchased 3,810,000 shares of the company's common stock for over $49 million. This transaction occurred on June 12, 2026, at a price of $13.12 per share, bringing his direct ownership to 573,883,879 shares and indirect ownership to 36,131,930 shares.
Summit Therapeutics co-CEO Robert Duggan acquires 3.81 million shares
Summit Therapeutics co-CEO Robert Duggan acquired 3.81 million shares of common stock at $13.12 per share on June 12, 2026, increasing his direct ownership to 573.88 million shares. The transaction was a private purchase, and the filing also detailed his significant indirect holdings through family trusts. Duggan is classified as a 10% owner and disclaims beneficial ownership of indirectly held securities except for pecuniary interest.
Summit Therapeutics Halts US$500m Offering After Ivonescimab Trial Results
Summit Therapeutics has withdrawn its proposed US$500 million public equity offering due to unfavorable market conditions, despite recent positive Phase II/III results for its drug ivonescimab in treating metastatic colorectal cancer and non-small cell lung cancer. This decision puts a spotlight on the company's future capital needs, especially given it is pre-revenue and needs funding for costly late-stage trials. While avoiding near-term dilution for shareholders, the halt creates an important juncture for investors to observe how management will fund its programs and navigate the market.
Summit Therapeutics stock rises after CEO share purchase
Summit Therapeutics Inc. (NASDAQ:SMMT) shares increased by 4% after co-chief executive officer Robert Duggan purchased 3.81 million shares of common stock at $13.12 per share. This transaction, a private purchase, significantly increases Duggan's direct holdings to 573.88 million shares, classifying him as a 10% owner of the company. The filing also detailed his indirect holdings through various family trusts.
Summit pulls $500M share sale a day after announcing it
Summit Therapeutics canceled its planned $500 million secondary share offering a day after announcing it, attributing the decision to "market conditions." This move comes despite a generally healthy environment for biotech share sales, as Summit's stock has struggled due to mixed data for its experimental lung cancer drug, ivonescimab, and ongoing investor debate about its efficacy. The company holds nearly $600 million in cash but faces significant annual R&D expenses, with analysts projecting cash exhaustion by 2027.
Summit Therapeutics (SMMT) Withdraws $500M Public Offering Amid Market Conditions
Summit Therapeutics (SMMT) has withdrawn its proposed $500 million public offering, citing unfavorable market conditions for raising capital to develop its drug candidate, ivonescimab. Despite a premarket stock rise and strong financial strength, the company has a low GF Score of 30/100, reflecting weaknesses in profitability and growth. Investors are advised to be cautious and monitor future developments.
Summit Therapeutics withdraws proposed underwritten offering citing market conditions
Summit Therapeutics (SMMT) announced the withdrawal of its previously proposed underwritten public offering, effective June 10, 2026. The company cited market conditions as the reason for terminating the offering, meaning no securities will be sold. An 8-K filing clarifies that this notice is not an offer or solicitation for sales.
Summit Therapeutics (NASDAQ: SMMT) pulls planned stock sale amid markets
Summit Therapeutics Inc. announced it has withdrawn its previously planned underwritten public offering of securities, effective June 10, 2026, citing unfavorable market conditions. As a result, no securities will be sold under this proposed transaction. This disclosure is made under Regulation FD and is not considered a "filed" report for liability purposes under Section 18 of the Exchange Act.
Summit Therapeutics (SMMT) Sees a 10.2% Decline
Summit Therapeutics (SMMT) experienced a 10.2% stock decline, with shares dropping to $12.83, leading to investor concern regarding the company's future prospects. Despite a stable financial strength rating of 7/10, the company's GF Score™ of 30/100 points to challenges in profitability and growth. The presence of 3 insider buying transactions totaling 250,000 shares over the past three months suggests some internal confidence, though overall market sentiment remains cautious.
Summit Therapeutics stock hits 52-week low at 13.14 USD
Summit Therapeutics (SMMT) stock has dropped to a 52-week low of $13.14, representing a 35% decline over the past year. Despite this, InvestingPro analysis suggests the stock is undervalued and oversold. The company recently announced a $500 million stock offering and presented positive Phase 3 trial data for ivonescimab, though analyst opinions are mixed regarding the global applicability of these results.
Super Micro Computer, Summit Therapeutics And Other Big Stocks Moving Lower In Wednesday's Pre-Market Ses
U.S. stock futures were down on Wednesday, with the Nasdaq futures falling by about 1%. Super Micro Computer Inc (NASDAQ: SMCI) shares dropped significantly after the company announced a proposed offering of $7 billion to fund AI server orders. Other stocks also experienced declines in pre-market trading, including BitVentures Limited, Frequency Electronics Inc, Horizon Quantum Holdings Ltd, Inventiva S.A., United Microelectronics Corporation, Summit Therapeutics Inc., Voyager Acquisition Corp., and Arteris, Inc.
Why Is SMMT Stock Tumbling Today?
Summit Therapeutics (SMMT) stock fell nearly 8% after the company announced a $500 million common stock offering. The proceeds from this offering, along with existing cash, will primarily fund the research and development of its lead cancer drug candidate, ivonescimab. Ivonescimab is an experimental cancer drug that has shown a 34% reduction in the risk of death in a Phase III clinical study for non-small cell lung cancer.
Summit Therapeutics files for $500M common stock offering; shares slide over 9%
Summit Therapeutics has filed a registration statement for a $500 million common stock offering, aiming to raise capital through the sale of its shares. This announcement led to a more than 9% drop in the company's stock value. The offering is anticipated to close concurrently with the previously announced acquisition of Akeso's oncology drug, ivonescimab, for Greater China development and commercialization rights.
Summit Therapeutics Announces Proposed Public Offering of Common Stock - June 9, 2026
Summit Therapeutics Inc. announced an underwritten public offering of $500.0 million of its common stock, with an option for underwriters to purchase an additional $75.0 million. The company plans to use the net proceeds, along with existing cash, to fund research and development for its lead product candidate, ivonescimab, and for general corporate purposes. J.P. Morgan, Goldman Sachs & Co. LLC, and Citigroup are the joint book-running managers for the offering.
Summit Therapeutics Launches $500 Million Common Stock Public Offering
Summit Therapeutics has announced a public offering of its common stock amounting to $500 million. This move aims to raise significant capital for the company, likely to fund ongoing research, development, and operational activities. The offering indicates Summit's strategy to strengthen its financial position and advance its pipeline.
Summit Therapeutics launches $500 million stock offering
Summit Therapeutics Inc. announced a $500 million underwritten public offering of common stock, with an option for underwriters to purchase an additional $75 million in shares. The biopharmaceutical company plans to use the net proceeds to fund research and development of its lead product candidate, ivonescimab, and for general corporate purposes. This offering comes as the company's shares are trading near their 52-week low, and while InvestingPro data suggests the stock is undervalued, the company remains unprofitable with a significant EBITDA loss.
Summit Therapeutics Announces Proposed Public Offering of Common Stock
Summit Therapeutics Inc. announced an underwritten public offering of $500.0 million of its common stock, with an option for underwriters to purchase an additional $75.0 million. The company plans to use the net proceeds, along with existing cash, to fund research and development for its lead product candidate, ivonescimab, and for general corporate purposes. J.P. Morgan, Goldman Sachs & Co. LLC, and Citigroup are acting as joint book-running managers for the offering.
Summit Therapeutics stock tumbles on $500M stock offering
Summit Therapeutics' shares dropped 12% after the announcement of a proposed $500 million public offering of common stock. The biotechnology company plans to use the proceeds, along with existing funds, to finance research and development for its lead product candidate, ivonescimab, and for general corporate purposes. The offering's completion, size, and terms remain subject to market conditions and other factors, with no assurance provided.
[424B5] Summit Therapeutics Inc. Prospectus Supplement (Debt Securities)
Summit Therapeutics Inc. has filed a prospectus supplement for a registered primary offering of $500.0 million in common stock, with a 30-day underwriter option for an additional $75.0 million and an active at-the-market program with $276.2 million remaining. The proceeds will fund the continued development of ivonescimab, including clinical trials for NSCLC and other solid tumors, and for general corporate purposes. Notably, the company acknowledges substantial doubt about its ability to continue as a going concern without further funding.
Summit Therapeutics stock tumbles on $500M stock offering
Summit Therapeutics Inc. shares dropped 12% after announcing a proposed public offering of $500 million in common stock. The biotechnology company plans to use the net proceeds, along with existing cash, to fund research and development for its lead product candidate, ivonescimab, and for general corporate purposes. The offering's completion and terms are subject to market conditions.
Summit Therapeutics Announces Proposed Public Offering Of Common Stock
Summit Therapeutics has announced a proposed public offering of its common stock. The news, reported by Reuters and Refinitiv, suggests the company is looking to raise capital through this offering. Further details were not provided in this brief announcement.
Summit Therapeutics (NASDAQ: SMMT) files shelf to offer common, preferred, debt
Summit Therapeutics Inc. (NASDAQ: SMMT) has filed a shelf registration on Form S-3, allowing it to offer various securities including common stock, preferred stock, and debt securities "from time to time" for general corporate purposes. The filing indicates that the company's common stock last traded at $14.11 on June 8, 2026, and includes a "going concern" warning due to substantial doubt about its ability to continue operations without additional funding. The specific terms, pricing, and offering amounts for future sales will be detailed in subsequent prospectus supplements.
Summit Therapeutics (SMMT) Is Down 6.0% After New Ivonescimab ASCO Data - Has The Bull Case Changed?
Summit Therapeutics' stock (SMMT) dropped 6.0% following new ivonescimab data presented at ASCO, related to colorectal and lung cancer. Despite strong objective responses and overall survival benefits seen in Phase II and III trials, the company's investment narrative still hinges on regulatory approvals and commercial uptake. Analysts' forecasts for 2029 revenue and earnings, alongside a fair value estimate significantly higher than the current price, suggest potential upside, but the risk of setbacks in ongoing Phase III trials remains a key concern.
Summit Therapeutics (SMMT) Is Down 6.0% After New Ivonescimab ASCO Data - Has The Bull Case Changed?
Summit Therapeutics experienced a 6.0% drop after presenting new Phase II and Phase III ivonescimab data at ASCO, particularly focusing on colorectal and lung cancer. Despite the strong objective responses shown, especially in first-line metastatic colorectal cancer, the company's investment narrative still hinges on regulatory approval and commercial uptake. The article highlights ivonescimab's potential across solid tumors and suggests that positive outcomes in ongoing Phase III trials could add a second major therapeutic pillar to Summit's portfolio.
Summit Therapeutics (SMMT) Co‑CEO associated trust purchases 100,000 shares at $14.60
Summit Therapeutics Co-CEO Robert W. Duggan reported an indirect open-market purchase of 100,000 shares of common stock at $14.60 per share through the Mahkam Zanganeh Revocable Trust. This transaction increased the trust's holdings to 25,824,474 shares. The filing also detailed Duggan's direct holdings of over 570 million shares and other indirect holdings associated with various trusts and family members, with a disclaimer of beneficial ownership except for pecuniary interest.
Summit Therapeutics (SMMT) Reveals Phase II AK112-206 Trial Data
Summit Therapeutics (SMMT) presented new clinical data from its Phase II AK112-206 trial for ivonescimab in metastatic colorectal cancer, showing a 70.8% objective response rate in combination with chemotherapy. This data compares favorably to standard treatments. Despite promising results, Piper Sandler recently cut SMMT's price target to $16, maintaining a Neutral rating, as investors weigh the replicability of positive trial outcomes in ongoing larger studies.
